- Home
- INVE vs MGX Comparison
INVE vs MGX Comparison
Compare INVE & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- MGX
- Stock Information
- Founded
- INVE 1990
- MGX 2018
- Country
- INVE United States
- MGX United States
- Employees
- INVE N/A
- MGX N/A
- Industry
- INVE Computer peripheral equipment
- MGX
- Sector
- INVE Technology
- MGX
- Exchange
- INVE Nasdaq
- MGX NYSE
- Market Cap
- INVE 74.2M
- MGX 62.1M
- IPO Year
- INVE 1997
- MGX 2024
- Fundamental
- Price
- INVE $3.12
- MGX $1.61
- Analyst Decision
- INVE Strong Buy
- MGX Strong Buy
- Analyst Count
- INVE 3
- MGX 4
- Target Price
- INVE $6.50
- MGX $13.00
- AVG Volume (30 Days)
- INVE 65.8K
- MGX 682.1K
- Earning Date
- INVE 08-07-2025
- MGX 08-13-2025
- Dividend Yield
- INVE N/A
- MGX N/A
- EPS Growth
- INVE N/A
- MGX N/A
- EPS
- INVE 3.12
- MGX N/A
- Revenue
- INVE $25,239,000.00
- MGX $45,263,000.00
- Revenue This Year
- INVE N/A
- MGX N/A
- Revenue Next Year
- INVE $9.00
- MGX $11.75
- P/E Ratio
- INVE $1.01
- MGX N/A
- Revenue Growth
- INVE N/A
- MGX N/A
- 52 Week Low
- INVE $2.86
- MGX $1.23
- 52 Week High
- INVE $4.35
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- INVE 45.58
- MGX 53.96
- Support Level
- INVE $3.10
- MGX $1.45
- Resistance Level
- INVE $3.25
- MGX $1.66
- Average True Range (ATR)
- INVE 0.12
- MGX 0.13
- MACD
- INVE -0.00
- MGX 0.01
- Stochastic Oscillator
- INVE 14.81
- MGX 72.13
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.